Light Mode
$20.87 ↑ +0.00 (+0.00%) Trading Up from the previous close of $20.87, $0.30 below the day’s high of $21.17
+6.13 (+41.59%) / 6M
Momentum, market sentiment, and recent alerts
CUE reads not so good: price sits above one of the two key moving averages, the 12-month move is +2884.0%.
Earnings, valuation, and balance sheet
Company profile and competitor comparison
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in advancing a portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its pipeline includes CUE-221, a novel anti-IgE antibody with a dual mechanism of action, and CUE-401, designed to regulate inflammation and drive Treg-mediated tolerance. The company was founded by Ronald D. Seidel III, Steven Almo, and Rodolfo Chaparro on December 31, 2014 and is headquartered in Boston, MA.
No peer group available for this symbol.
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.